Pharmaceutical Executive Daily: China's Latest Policy Guidance
In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement access for truly innovative drugs, Parabilis Medicines surges more than 45 percent on its first day of trading on Nasdaq, and Pharmaceutical Executive speaks with Eli Lilly's Sarah O'Keeffe, Group Vice President of Product Research and Development, on how the company's $4.5 billion Medicine Foundry is designed to transform the discovery-to-production handoff and accelerate speed to patient.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg
Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO
Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO
The Ron Lanton Report: From Innovation to Infrastructure
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.